We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Blood Clotting Causes Significant Mortality in COVID-19 Patients

By LabMedica International staff writers
Posted on 11 May 2020
Print article
Image: The ACL Top 550 hemostasis analyzer (Photo courtesy of Werfen).
Image: The ACL Top 550 hemostasis analyzer (Photo courtesy of Werfen).
Although the underlying pulmonary pathophysiology remains incompletely understood, severe COVID-19 infection is associated with a marked alveolar inflammatory cell infiltrate, together with a systemic cytokine storm response.

Consistent with the hypothesis that coagulation activation may play a role in COVID-19 pathogenesis, post-mortem studies have highlighted marked pathological changes specifically involving the lung microvasculature, including disseminated micro-thrombi and significant hemorrhagic necrosis.

Clinical scientists collaborating with those at the Royal College of Surgeons University of Medicine and Health Sciences (Dublin, Ireland) recruited consecutive adult patients with COVID-19 from March 13th to April 10th 2020. Hemostasis assays were performed including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and D-dimer levels. The PT, APTT and Fibrinogen assays were measured on the ACL Top 550 analyzer (Werfen, Barcelona, Spain).

Coagulation testing performed on admission in the total cohort demonstrated normal PT and APTT. In contrast, plasma D-dimer levels were significantly increased (median 732; range 200 to 10,000 ng/mL). D-dimer levels were above the normal range in 67% of the total cohort on admission. Fibrinogen levels were significantly increased (median 4.7; range 3.0 to 9.9 g/L) on admission, with levels remaining persistently elevated throughout hospitalization. The team noted that that they had found that abnormal blood clotting occurring in Irish patients with severe COVID-19 infection, causing micro-clots within the lungs. They also found that Irish patients with higher levels of blood clotting activity had a significantly worse prognosis and were more likely to require ICU admission.

James S. O'Donnell, a Professor and Consultant Hematologist and senior author of the study, said, “Our novel findings demonstrate that COVID-19 is associated with a unique type of blood clotting disorder that is primarily focused within the lungs and which undoubtedly contributes to the high levels of mortality being seen in patients with COVID-19. In addition to pneumonia affecting the small air sacs within the lungs, we are also finding hundreds of small blood clots throughout the lungs. This scenario is not seen with other types of lung infection, and explains why blood oxygen levels fall dramatically in severe COVID-19 infection. Understanding how these micro-clots are being formed within the lung is critical so that we can develop more effective treatments for our patients, particularly those in high risk groups.” The study was published on April 24, 2020 in the British Journal of Haematology.

Related Links:
Royal College of Surgeons University of Medicine and Health Sciences
Werfen



Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.